MedTrace Logo

Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

NCT03296033 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2023-10-05

Study results available
· View outcomes & findings →

Summary

The main objective of this study is to determine the time interval following the last treatment dose of enoxaparin at which the amount of anti-Xa level activity is reliably less than 0.2 international unit per milliliter (IU/mL) in patients presenting for elective surgery.

Conditions

  • Anticoagulants and Bleeding Disorders
  • Surgery
  • Regional Anesthesia Morbidity

Interventions

DRUG

Enoxaparin

The intervention is the implementation of a 36-hour time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing.

DRUG

Enoxaparin

This is the historical control arm. 24 hours removed from their last dose (time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing)

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Daryl S Henshaw, MD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-24
Primary Completion
2022-01-14
Completion
2022-01-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03296033 on ClinicalTrials.gov